Latest news

24 January 2023 09:01

Helsinn and Immedica enter exclusive partnership for commercialization of cancer supportive care products in core European markets

LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023– Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, and Immedica Pharma AB, a pharmaceutical company focused on commercialisation of rare and specialty care products, today announce that the companies have

21 December 2022 14:02

Ravicti® (glycerol phenylbutyrate) approved by the Department of Health in Hongkong for the treatment of Urea Cycle Disorders

Ravicti® (glycerol phenylbutyrate) approved by the Department of Health in Hongkong for the treatment of Urea Cycle Disorders
Immedica Pharma, a pharmaceutical company focused on commercialisation of rare and specialty care products, and Winhealth Pharma today announce that Ravicti® (Glycerol phenylbutyrate) has been approved by the Department of Health in Hongkong for the treatment of urea cyc

31 October 2022 12:49

Top-line results from phase 3 SIERRA trial of Iomab-B announced

Immedica’s partner Actinium Pharmaceuteuticals Inc. has announced positive top-line results from the pivotal phase 3 SIERRA trial of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia.

Please read Actinium’s full press release below.
Immedica contacts:
Anders Edvell
Chief Executive Officer
anders.edvell@immedica.com
+46 705 4461 26
Linda Holmströ

28 October 2022 12:10

Strong growth and recruitments required more office space

Immedica Pharma AB, a pharmaceutical company focused on commercialization of rare and specialty diseases has recently moved its head quarter to the newly established Life City near Torsplan in Stockholm. Immedica is one of several pharmaceutical companies that are located at the new facilities on Solnavägen.
According to a report from Stockholms Handelskammare1, the Life Science sector in Stoc

30 September 2022 10:41

RAVICTI® (glycerol phenylbutyrate) accepted and granted Priority Review for the New Drug Application (NDA) in China

Immedica Pharma AB is pleased to announce that RAVICTI® (glycerol phenylbutyrate), has been accepted and granted Priority Review for the New Drug Application (NDA) in China. This has been presented earlier by our partner WinHealth. In April, another submission for RAVICTI® Market Authorisation Approval was accepted by the Department of Health (DoH) in HongKong.

1 September 2022 11:52

Immedica welcomes Linda Holmström as Head of Communication

It is with great pleasure we today welcome Linda Holmström, who is an experienced stock exchange- and corporate brand communicator. Linda will take the role as Head of Communication and be responsible for both our external corporate branding including ESG and sustainability communication as well as being tightly involved in our European launches, with focus on our digital platforms and interfaces

24 August 2022 10:30

Immedica Pharma and Innovative Medicines announces ANMAT (Argentina) and INVIMA (Colombia) filing acceptance of RAVICTI® (glycerol phenylbutyrate)

Immedica Pharma and Innovative Medicines announces ANMAT (Argentina) and INVIMA (Colombia) filing acceptance of RAVICTI® (glycerol phenylbutyrate), a adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs).